IOVANCE BIOTHERAPEUTICS INC

IOVA is the Nasdaq ticker symbol for Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company. The company focuses on developing and commercializing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. IOVA stock represents an ownership stake in this biopharmaceutical firm, which is headquartered in San Carlos, California.

Recent performance for IOVA can be checked on the stock detail page, which displays up-to-date price changes and charts. As a clinical-stage biotech, its stock often reacts to clinical trial updates, regulatory news, and financing activities. For the latest performance figures, please refer to the real-time data provided on this page.

IOVA is listed on the Nasdaq Global Select Market and generally experiences active trading, with daily volume that can vary based on news and market conditions. Its liquidity is supported by its inclusion in major indices and coverage by multiple analysts. For current trading volume and liquidity metrics, check the latest data on the IOVA stock page.

Because IOVA is a clinical-stage biotech with no approved products generating significant revenue, traditional valuation metrics like P/E are not meaningful. Investors often assess its pipeline, cash position, and potential market opportunity for its therapies. Valuation may also be compared using price-to-book or enterprise value relative to research and development progress. For specific metrics, refer to the financial data on this page.

Key risks for IOVA include clinical trial failures, regulatory delays, and competition in the immunotherapy space. As a development-stage company, it may require additional capital, leading to dilution. Commercialization risks, manufacturing challenges, and dependence on key personnel also apply. Additionally, biotech stocks are often volatile and sensitive to news and market sentiment.

Iovance Biotherapeutics does not currently pay dividends. As a clinical-stage biotech, the company reinvests earnings, if any, into research and development. Therefore, IOVA is not suitable for income-focused investors. For any changes to this policy, please refer to the latest company announcements or the dividend section on this page.